The DPP4 inhibitor use was found to be a significant predictor of thromboembolism during hospitalization, with an adjusted OR of 2.249 (95% CI: 1.073–4.713) and a p-value of 0.032. This evidence concerns the gene DPP4 and Thromboembolism.